Clinical review report: Riociguat (Adempas)
The objective of this systematic review is to evaluate the beneficial and harmful effects of riociguat 0.5 mg, 1 mg, 1.5 mg, 2 mg, and 2.5 mg tablets for the treatment of pulmonary arterial hypertension in adults (World Health Organization [WHO] functional class II or III)
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
December 2015, 2015
|
| Series: | CADTH common drug review
|
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | The objective of this systematic review is to evaluate the beneficial and harmful effects of riociguat 0.5 mg, 1 mg, 1.5 mg, 2 mg, and 2.5 mg tablets for the treatment of pulmonary arterial hypertension in adults (World Health Organization [WHO] functional class II or III) |
|---|---|
| Physical Description: | 1 PDF file (74 pages) illustrations |